Wednesday, 24 January 2007

Eliminating Risky Business - Neptune to Launch Risk-Benefit Study

In light of recent events with regards to safety issues with competing products and companies in the "cholesterol" space, Neptune has initiated a population-based risk-benefit analysis study for NKO™ in the management of dyslipidemia. Click here for the release.
As NKO™ has been out on the market for over 4 years with no reports of serious adverse side effects, Neptune expects that this study will officially validate and demonstrate NKO™'s safety and effectiveness with a low risk-benefit ratio.

The study will be conducted by a team of renowned researchers affiliated with McGill University and University of Montreal.
It is important to note that the Risk-Benefit Analysis Study is separate from the "Phase" studies. Given recent developments related to high risks in taking drugs to increase HDL cholesterol, Neptune is providing formal validation that will set it apart from the crowd.
Two pharmaceutical products for cholesterol regulation have made headlines lately: safety concerns caused Pfizer's Torcetrapib to be pulled from further development. Liponex's CRD5 trials were altered due to patient side effects.
Although the study seems similar to previous analysis conducted by the company, it will provide further, formal validation for what Neptune has already stated - that NKO™ has not been found to be harmful to anyone who has taken it and is likely to comfort potential partners regarding the safety of NKO while increasing HDL.